Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04354246 | COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies | PHASE1 | COMPLETED | 94 | — | — | Mar 31, 2020 | Apr 1, 2026 | May 12, 2026 | 9 | United States |
Incidence of subjects with Adverse Events (AEs) as per CTCAE v5.0 and Dose-Limiting Toxicities (DLTs).
Evaluation of a dose of COM902 monotherapy and in combination with COM701 that is well tolerated by subjects.
Evaluation of parameters of COM902 monotherapy or in combination with COM701 exposure such as Maximum Plasma Concentration \[Cmax\]).
Incidence of subjects on the Triplet combination (COM902 + COM701 + Pembrolizumab) with Adverse Events (AEs) per CTCAE v5.0.
Evaluation of PK parameters e.g., Cmax.
| Arm | Type | Description |
|---|---|---|
| COM902 monotherapy dose escalation. | EXPERIMENTAL | Monotherapy dose escalation. COM902 monotherapy administered IV every 3 weeks in sequential dose escalation. Up to 7 dose escalation cohorts may be evaluated until a maximum tolerated dose or recommended dose for expansion (RDFE) is identified. |
| Dual combination (COM902 + COM701) for evaluation of safety/tolerability (both at RDFE). | EXPERIMENTAL | COM902 will be combined with COM701 for evaluation of safety and tolerability. All study drugs will be administered IV every 3 weeks. |
| COM902 monotherapy cohort expansion at RDFE. | EXPERIMENTAL | COM902 monotherapy at the RDFE - in subjects with multiple myeloma. COM902 will be administered IV every 3 weeks. |
| COM902 + COM701 combination cohort expansion both at RDFE. | EXPERIMENTAL | COM902 + COM701 (both at the RDFE) evaluated in subjects with select tumor types who have exhausted standard of care treatment: HNSCC, CRC (MSS), NSCLC. All study drugs will be administered IV every 3 weeks. |
| MSS-CRC Triplet combination (COM902 + COM701 + Pembrolizumab). | EXPERIMENTAL | Triplet combination of COM902 + COM701 + Pembrolizumab evaluated in subjects with MSS-CRC. All study drugs will be administered IV every 3 weeks. |
| Platinum resistant ovarian cancer Triplet combination (COM902 + COM701 + Pembrolizumab). | EXPERIMENTAL | Triplet combination of COM902 + COM701 + Pembrolizumab evaluated in subjects with PROC. All study drugs will be administered IV every 3 weeks. |
| Name | Type | Description |
|---|---|---|
| Dose escalation: COM902 monotherapy. | DRUG | COM902 monotherapy administered IV every 3 weeks in sequential dose escalation doses in cohorts of subjects. |
| Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE) | COMBINATION_PRODUCT | Both study drugs will be evaluated at the RDFE for assessment of safety and tolerability. All study drugs will be administered IV every 3 weeks. |
| Cohort expansion: COM902 (RDFE) monotherapy. | DRUG | COM902 monotherapy (RDFE) in subjects with multiple myeloma. COM902 will be administered IV every 3 weeks. |
| Cohort expansion: COM902 in combination with COM701 (both at the RDFE). | DRUG | COM902 in combination with COM701 (both at RDFE) in subjects with select tumor types who have exhausted standard treatment - HNSCC, CRC (MSS), NSCLC. All study drugs will be administered IV every 3 weeks. |
| Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab. | COMBINATION_PRODUCT | Triplet combination of COM902 + COM701 + Pembrolizumab administered IV every 3 weeks. |
Key Inclusion Criteria: * Subjects with histologically/cytologically confirmed advanced malignancy (solid tumor) who must have exhausted all available standard therapy, or not a candidate for standard therapy. * Subject is able to provide written, informed consent before initiation of any study rel...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |